The postoperative pathology results showed that with a diagnosis of Luminal HER2-type, the 10-year breast cancer mortality risk using a prognostic tool for early-stage breast cancer “Predict” (https://breast.predict.nhs.uk) was 5%, while endocrine therapy + chemotherapy + anti-HER2 therapy resulted in a 1% reduction in mortality risk. This evidence concerns the gene ERBB2 and breast cancer.